Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 7/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | HTR6 | P50406 | 8/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2480696 | 0.92 | SIRT6 (0.71) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL13395270 | 0.87 | SIRT6 (0.54) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL27997682 | 0.86 | SIRT6 (0.75) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL30532598 | 0.86 | SIRT6 (0.75) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL4723486 | 0.84 | L3MBTL1 (0.51) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL170932 | 0.83 | HPGD (0.75) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL16003490 | 0.83 | MAPT (0.53) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL17032635 | 0.83 | MAPT (0.65) | SIRT6MAPTALDH1A1MAPK1 | |
| SCHEMBL24267633 | 0.82 | SIRT6 (0.69) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL2910036 | 0.82 | SIRT6 (0.69) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024051667-A1 | SUBSTITUTED TRIAZOLE COMPOUND HAVING AXL INHIBITORY ACTIVITY | 南京正大天晴制药有限公司 | 2024-03-14 | — | — | WO | disclosed |
| WO-2024046221-A1 | EGFR INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-03-07 | — | — | WO | disclosed |
| EP-3966207-B1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230039712-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-02-09 | — | — | US | disclosed |
| US-11530206-B2 | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-12-20 | — | — | US | disclosed |
| US-20200354352-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2020-11-12 | — | — | US | disclosed |
| EP-2509602-B9 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-11-01 | — | — | EP | disclosed |
| EP-2509602-B1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-01-25 | — | — | EP | disclosed |
| US-9303033-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2016-04-05 | — | — | US | disclosed |
| US-9303033-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2016-04-05 | — | — | US | disclosed |
| WO-2009108912-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009108912-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009024824-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| US-20090042904-A1 | Substituted Phenly-Piperazine Compounds, Their Preparation And Use In Medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| US-20090042904-A1 | Substituted Phenly-Piperazine Compounds, Their Preparation And Use In Medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| US-20090042904-A1 | Substituted Phenly-Piperazine Compounds, Their Preparation And Use In Medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| CN-101142201-A | Substituted phenyl-piperazine compounds, their preparation and use in medicaments | ESTEVE LABOR DR (ES) | 2008-03-12 | — | — | CN | disclosed |
| EP-1844031-A1 | SUBSTITUTED PHENYL-PIPERAZINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-10-17 | — | — | EP | disclosed |
| EP-1695971-A1 | Substituted phenyl-piperazine compounds, their preparation and use in medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-08-30 | — | — | EP | disclosed |
| WO-2006069807-A1 | SUBSTITUTED PHENYL-PIPERAZINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039712-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | SIRT6 651/4885MAPT 817/4885ALDH1A1 2271/4885 |
| US-11530206-B2 | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | BECN1, SQSTM1, ATG7 | SIRT6 651/4885MAPT 817/4885ALDH1A1 2271/4885 |
| US-20200354352-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | SIRT6 651/4885MAPT 817/4885ALDH1A1 2271/4885 |
| US-20090042904-A1 | Substituted Phenly-Piperazine Compounds, Their Preparation And Use In Medicaments | HTR6, HTR5A, HTR7 | SIRT6 270/4885MAPT 2541/4885ALDH1A1 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.